No choice efgolden, they have to stick together. ATHX offers perfect diversity with the Pfizer collaboration for inflammatory bowel and their AMI collaboration with Angiotech. The overlap in technology is exactly what is needed for a stem cell breakthrough. ATHX is going to run out of cash and OSIR will need their IP.
Imagine this scenario, Prochymal is approved in Canada and we dilute to take on ATHX. It would still be worth it. It is going to take these kinds of bold moves to make it in this economy.